Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPRINT MeetURO trial of pembrolizumab plus enfortumab vedotin in collecting duct and renal medullary carcinoma
2024-511587-93-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and enfortumab vedotin in collecting duct carcinoma (CDC) and Kidney medullary carcinoma (RMC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Objective response rate. Planned start Feb 2025; status: authorised.
02
Drugs
pembrolizumabenfortumab vedotin
03
Conditions
collecting duct carcinoma (CDC)Kidney medullary carcinoma (RMC)
Beyond the preview
Go deeper on 2024-511587-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511587-93-00.